# Shop Tirzepatide

> An independent product-design lens on the tirzepatide research record — every SURPASS, every SURMOUNT, organized like a design system.

Shop Tirzepatide is an editorial project that summarizes the peer-reviewed
literature on tirzepatide, a dual GIP and GLP-1 receptor agonist that is
FDA-approved for type 2 diabetes (2022), chronic weight management (2023),
and obstructive sleep apnea in adults with obesity (2024).

We do not sell, prescribe, dispense, or ship any product. This is not a
pharmacy, telehealth service, or compounding facility. The site is editorial.

## Pages

- [Overview](https://shoptirzepatide.com/index.md): An independent editorial summary of the tirzepatide research literature — mechanism of action, every SURPASS and SURMOUNT trial, dose titration per the FDA label, and the safety record.
- [Research](https://shoptirzepatide.com/research.md): Trial-by-trial summary of the phase 3 program: SURPASS in type 2 diabetes, SURMOUNT in obesity, SURMOUNT-OSA in sleep apnea, SUMMIT in HFpEF, SYNERGY-NASH in MASH. Citations to NEJM, Lancet, and JAMA.
- [Dosage](https://shoptirzepatide.com/dosage.md): The FDA-labeled tirzepatide dose titration schedule (2.5 mg starting dose, monthly steps to 5, 7.5, 10, 12.5, 15 mg), elimination half-life, route, storage, renal/hepatic considerations.
- [FAQ](https://shoptirzepatide.com/faq.md): Answers to common questions: mechanism, SURMOUNT-1 weight loss, titration, side effects, half-life, cardiovascular outcomes, sleep apnea, MASH, what happens after stopping, compounded status.
- [References](https://shoptirzepatide.com/references.md): All 19 primary sources cited across the site, with DOIs and PubMed links — SURPASS, SURMOUNT, SURMOUNT-OSA, SUMMIT, SYNERGY-NASH, SURPASS-CVOT, mechanism, and PK publications.
- [About](https://shoptirzepatide.com/about.md): What this site is — and what it is not. An independent editorial project. Not a clinic, not a pharmacy, not a vendor.
- [Contact](https://shoptirzepatide.com/contact.md): Editorial correspondence — corrections and citation requests. No clinical questions. No product sales.

## Compound

- INN: tirzepatide
- Class: dual GIP and GLP-1 receptor co-agonist (39-amino acid synthetic peptide)
- Route: subcutaneous, once weekly
- Half-life: ~5 days
- Status: FDA-approved by prescription (T2DM 2022, obesity 2023, OSA 2024)

## Editorial conventions

- INN-only naming. No brand names anywhere.
- Every quantitative claim cites a primary source on /references.
- Disclaimer on every page: not medical advice; this site does not sell any product.